Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma

Pigment Cell and Melanoma Research

Volumn 26, Issue 6, 2013, Pages 852-860

  Dutton Regester, Ken ^a   Kakavand, Hojabr ^b   Aoude, Lauren G ^a   Stark, Mitchell S ^a   Gartside, Michael G ^a   Johansson, Peter ^a   O'Connor, Linda ^a   Lanagan, Cathy ^a   Tembe, Varsha ^b,c,d   Pupo, Gulietta M ^b,c,d   Haydu, Lauren E ^b,d   Schmidt, Christopher W ^a   Mann, Graham J ^b,c,d   Thompson, John F ^b,d,e   Scolyer, Richard A ^b,d,e   Hayward, Nicholas K ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Melanoma of unknown primary; Mutation profile; Sequencing

Indexed keywords

B RAF KINASE;

ADULT; AGED; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CUTANEOUS MELANOMA; EXOME; FEMALE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE DISSECTION; MALE; MELANOMA; MELANOMA OF UNKNOWN PRIMARY; MUTAGENESIS; MUTATION RATE; ONCOGENE N RAS; PATHOGENESIS; POINT MUTATION; SKIN SURFACE; SOMATIC MUTATION; SUN EXPOSURE; ULTRAVIOLET RADIATION;

MELANOMA OF UNKNOWN PRIMARY; MUTATION PROFILE; SEQUENCING;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; EXOME; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASMS, UNKNOWN PRIMARY; SKIN NEOPLASMS; SUNLIGHT;

EID: 84886239930     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12153     Document Type: Article

References (54)

1. Azimi, F., Scolyer, R.A., Rumcheva, P., Moncrieff, M., Murali, R., McCarthy, S.W., Saw, R.P., and Thompson, J.F. (2012). Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J. Clin. Oncol. 30, 2678-2683.
2. Bailey, J.A., Yavor, A.M., Massa, H.F., Trask, B.J., and Eichler, E.E. (2001). Segmental duplications: organization and impact within the current human genome project assembly. Genome Res. 11, 1005-1017.
3. Berger, M.F., Hodis, E., Heffernan, T.P. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506.
4. Brahmer, J.R., Tykodi, S.S., Chow, L.Q. et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465.
5. Camacho, L.H., Antonia, S., Sosman, J. et al. (2009). Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27, 1075-1081.
6. Castellano, M., Pollock, P.M., Walters, M.K., Sparrow, L.E., Down, L.M., Gabrielli, B.G., Parsons, P.G., and Hayward, N.K. (1997). CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res. 57, 4868-4875.
7. Cormier, J.N., Xing, Y., Feng, L., Huang, X., Davidson, L., Gershenwald, J.E., Lee, J.E., Mansfield, P.F., and Ross, M.I. (2006). Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 106, 2012-2020.
8. Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
9. Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346.
10. Dasgupta, T., Bowden, L., and Berg, J.W. (1963). Malignant melanoma of unknown primary origin. Surg. Gynecol. Obstet. 117, 341-345.
11. Dutton-Regester, K., and Hayward, N.K. (2012). Whole genome and exome sequencing of melanoma: a step toward personalized targeted therapy. Adv. Pharmacol. 65, 399-435.
12. Dutton-Regester, K., Aoude, L.G., Nancarrow, D.J. et al. (2012a). Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene. Genes Chromosom. Cancer 51, 452-461.
13. Dutton-Regester, K., Irwin, D., Hunt, P. et al. (2012b). A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol. Cancer Ther. 11, 888-897.
14. Everson, T.C. (1964). Spontaneous regression of cancer. Ann. N. Y. Acad. Sci. 114, 721-735.
15. Falchook, G.S., Long, G.V., Kurzrock, R. et al. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901.
16. Flaherty, K.T., Infante, J.R., Daud, A. et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
17. Furney, S.J., Turajlic, S., Fenwick, K. et al. (2012). Genomic characterisation of acral melanoma cell lines. Pigment Cell Melanoma Res. 25, 488-492.
18. Harbour, J.W., Onken, M.D., Roberson, E.D., Duan, S., Cao, L., Worley, L.A., Council, M.L., Matatall, K.A., Helms, C., and Bowcock, A.M. (2010). Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410-1413.
19. Hauschild, A., Grob, J.J., Demidov, L.V. et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
20. Hodi, F.S., O'Day, S.J., McDermott, D.F. et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
21. Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
22. Jakob, J.A., Bassett Jr, R.L., Ng, C.S. et al. (2012). NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4014-4023.
23. Kamposioras, K., Pentheroudakis, G., Pectasides, D., and Pavlidis, N. et al. (2011). Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit. Rev. Oncol. Hematol. 78, 112-126.
24. Koboldt, D.C., Chen, K., Wylie, T., Larson, D. E., McLellan, M. D., Mardis, E. R., Weinstock, G. M., Wilson, R.K., and Ding, L. et al. (2009). VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 25, 2283-2285.
25. Krauthammer, M., Kong, Y., Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
26. Lee, C.C., Faries, M.B., Wanek, L.A., and Morton, D.L. et al. (2008). Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J. Clin. Oncol. 26, 535-541.
27. Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760.
28. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., and Durbin, R. et al. (2009). The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079.
29. Long, G.V., Menzies, A.M., Nagrial, A.M., Haydu, L.E., Hamilton, A.L., Mann, G.J., Hughes, T.M., Thompson, J.F., Scolyer, R.A., and Kefford, R.F. et al. (2011). Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239-1246.
30. Long, G.V., Trefzer, U., Davies, M.A. et al. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087-1095.
31. Lopez, G.Y., Reitman, Z.J., Solomon, D., Waldman, T., Bigner, D.D., McLendon, R.E., Rosenberg, S.A., Samuels, Y., and Yan, H. (2010). IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem. Biophys. Res. Commun. 398, 585-587.
32. Mann, G.J., Pupo, G.M., Campain, A.E et al. (2013). BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J. Invest. Dermatol. 133, 509-517.
33. Mardis, E.R., Ding, L., Dooling, D.J. et al. (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066.
34. Menzies, A.M., Haydu, L.E., Visintin, L., Carlino, M.S., Howle, J.R., Thompson, J.F., Kefford, R.F., Scolyer, R.A., and Long, G.V. (2012). Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 18, 3242-3249.
35. Nikolaev, S.I., Rimoldi, D., Iseli, C. et al. (2012). Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 44, 133-139.
36. Pavey, S., Johansson, P., Packer, L. et al. (2004). Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23, 4060-4067.
37. Pleasance, E.D., Cheetham, R.K., Stephens, P.J. et al. (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196.
38. Prens, S.P., van der Ploeg, A.P., van Akkooi, A.C., van Montfort, C.A., van Geel, A.N., de Wilt, J.H., Eggermont, A.M., and Verhoef, C. (2011). Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site. Ann. Surg. Oncol. 18, 3586-3592.
39. Ridolfi, R.L., Rosen, P.P., and Thaler, H. (1977). Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance. Cancer 39, 164-171.
40. Rizos, H., Darmanian, A.P., Indsto, J.O., Shannon, J.A., Kefford, R.F., and Mann, G.J. (1999). Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells. Melanoma Res. 9, 10-19.
41. Shenoy, B.V., Fort 3rd, L., and Benjamin, S.P. (1987). Malignant melanoma primary in lymph node. The case of the missing link. Am. J. Surg. Pathol. 11, 140-146.
42. Shibata, T., Kokubu, A., Miyamoto, M., Sasajima, Y., and Yamazaki, N. (2011). Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am. J. Pathol. 178, 1395-1402.
43. Smith Jr, J.L., and Stehlin Jr, J.S. (1965). Spontaneous regression of primary malignant melanomas with regional metastases. Cancer 18, 1399-1415.
44. Stark, M., and Hayward, N. (2007). Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 67, 2632-2642.
45. Stark, M.S., Woods, S.L., Gartside, M.G. et al. (2012). Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 44, 165-169.
46. Stefansson, B., and Brautigan, D.L. (2007). Protein phosphatase PP6 N terminal domain restricts G1 to S phase progression in human cancer cells. Cell Cycle 6, 1386-1392.
47. Topalian, S.L., Hodi, F.S., Brahmer, J.R. et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454.
48. Tos, T., Klyver, H., and Drzewiecki, K.T. (2011). Extensive screening for primary tumor is redundant in melanoma of unknown primary. J. Surg. Oncol. 104, 724-727.
49. Turajlic, S., Furney, S.J., Lambros, M.B. et al. (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res. 22, 196-207.
50. Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O'Brien, J.M., Simpson, E.M., Barsh, G.S., and Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599-602.
51. Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B. et al. (2010). Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 2191-2199.
52. Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164.
53. Wei, X., Walia, V., Lin, J.C. et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442-446.
54. Yan, H., Parsons, D.W., Jin, G. et al. (2009). IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773.